Fundraising FoxvenBio Global Strategic — 2021 Investments
6 investments dated 2021 · listed companies and verified rows first · show all
Artiva Bio is a clinical-stage biotechnology company developing NK cell-based therapies for autoimmune diseases, designed to be manufactured at scale and delivered in community settings.
BiotechHealthtechMedical DevicesSan Diego, US
Jennifer Bush(Executive Officer)inThomas J. Farrell(Executive Officer)Fred Aslan(Executive Officer, Director)inJason Litten(Executive Officer)inEsther van den Boom(Executive Officer)Peter Flynn(Executive Officer)in
Board seatYvonne Yamanaka· per SEC Form D · $120M raise · filed Apr 2021
Co-investors5AM VenturesEcoR1 CapitalRA CapitalvenBio PartnersWellington Management
Impel Pharmaceuticals develops therapies for diseases with high unmet medical needs by pairing established drugs with its proprietary upper-nasal drug delivery technology.
BiotechHealthtechMedical DevicesSeattle, US
John D. Hoekman(Executive Officer, Director)in
BoardMichael Hite(Director)Stewart Parker(Director)
Board seatAaron Royston· per SEC Form D · $1.9M raise · filed Apr 2021
Co-investors5AM VenturesB Capital GroupvenBio PartnersWestlake Village BioPartners
.jpeg){kind=logo}
Neurogastrx is a biopharmaceutical company developing therapies for patients with gastrointestinal disorders.
BiotechHealthtechWoburn, US
Cyril De Colle(Founder)inJAMES DETORE(Executive Officer)JAMES O'MARA(Executive Officer, Director)inPAUL ROGERS(Executive Officer)in
BoardDAVID ALLISON(Director)inKLAUS VEITINGER(Director)in
Board seatAaron Royston· per SEC Form D · filed Jul 2021
Co-investors5AM VenturesOrbiMedSamsara BioCapitalvenBio PartnersVivo CapitalRTW Investments L.P.+1 more
HealthtechIrvine, US
Kenny Chang(Executive Officer)W. Ronald Redmond(Director)Vijay Dhaka(Executive Officer)Philong Pham(Executive Officer, Director)Hongsheng Tong(Executive Officer, Director)
Board seatAaron Royston· per SEC Form D · $112M raise · filed Sep 2021
Co-investorsBlackRockEndeavour VisionMVM Life Science PartnersRTW Investments L.P.Soleus CapitalVivo Capital
Tallac Therapeutics is a clinical-stage biopharmaceutical company developing oligonucleotide-based antibody conjugates (TRAAC candidates) designed to deliver immune-activating agents to tumor microenvironments for oncology indications.
BiotechHealthtechMedical DevicesBurlingame, US
Hong Wan(Executive Officer, Director)in
BoardRan Geng(Director)Michael Carusi(Director)Isaac Cheng(Director)Christine Brennan(Director)
Board seatCorey Goodman· per SEC Form D · $61.6M raise · filed Jul 2021
Co-investorsLightstone VenturesMRL Ventures FundvenBio PartnersMatrix Partners China
San Diego, US
Mark S. Forman(Executive Officer)inMatthew Moore(Executive Officer)inJohn Nuss(Executive Officer)inJigar Choksey(Director)Martin Auster(Executive Officer)inChristopher W. Krueger(Executive Officer)
Board seatAaron RoystonRichard Gaster· per SEC Form D · $51M raise · filed Sep 2021
Co-investorsNew Science VenturesThird Point VenturesvenBio PartnersWellington ManagementSilverArc Private
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.